These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31853881)

  • 1. Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Paulsen JS; Downing NR; Ready R; Perlmutter JS; Cella D; Chou KL; McCormack MK; Barton S; Lai JS
    Qual Life Res; 2020 May; 29(5):1393-1403. PubMed ID: 31853881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Roché MW; Ready RE; Perlmutter JS; Chou KL; Barton SK; McCormack MK; Stout JC; Cella D; Miner JA; Paulsen JS
    Qual Life Res; 2020 Dec; 29(12):3419-3439. PubMed ID: 32813263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with huntington's disease.
    Carlozzi NE; Boileau NR; Chou KL; Ready RE; Cella D; McCormack MK; Miner JA; Dayalu P
    Mov Disord; 2020 Feb; 35(2):326-336. PubMed ID: 31724237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness to Change Over Time: An Examination of the Neuro-QoL Social Function Measures in Persons with Huntington's Disease.
    Carlozzi NE; Boileau NR; Hahn EA; Barton SK; Cella D; McCormack MK; Ready RE
    J Huntingtons Dis; 2020; 9(1):83-97. PubMed ID: 31744014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures.
    Lai JS; Goodnight S; Downing NR; Ready RE; Paulsen JS; Kratz AL; Stout JC; McCormack MK; Cella D; Ross C; Russell J; Carlozzi NE
    Qual Life Res; 2018 Mar; 27(3):811-822. PubMed ID: 29222609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?
    Carlozzi NE; Schilling S; Kratz AL; Paulsen JS; Frank S; Stout JC
    Qual Life Res; 2018 Oct; 27(10):2541-2555. PubMed ID: 29909483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.
    Boileau NR; Stout JC; Paulsen JS; Cella D; McCormack MK; Nance MA; Frank S; Lai JS; Carlozzi NE
    J Huntingtons Dis; 2017; 6(3):201-215. PubMed ID: 28968239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.
    Carlozzi NE; Goodnight S; Kratz AL; Stout JC; McCormack MK; Paulsen JS; Boileau NR; Cella D; Ready RE
    J Huntingtons Dis; 2019; 8(4):467-482. PubMed ID: 31424415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures.
    Carlozzi NE; Hahn EA; Goodnight SM; Kratz AL; Paulsen JS; Stout JC; Frank S; Miner JA; Cella D; Gershon RC; Schilling SG; Ready RE
    Psychol Assess; 2018 Apr; 30(4):450-458. PubMed ID: 28557480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).
    Carlozzi NE; Schilling SG; Lai JS; Paulsen JS; Hahn EA; Perlmutter JS; Ross CA; Downing NR; Kratz AL; McCormack MK; Nance MA; Quaid KA; Stout JC; Gershon RC; Ready RE; Miner JA; Barton SK; Perlman SL; Rao SM; Frank S; Shoulson I; Marin H; Geschwind MD; Dayalu P; Goodnight SM; Cella D
    Qual Life Res; 2016 Oct; 25(10):2441-2455. PubMed ID: 27522213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.
    Carlozzi NE; Boileau NR; Roberts A; Dayalu P; Hanifan DL; Miner JA; Claassen D; Provost EM
    Qual Life Res; 2021 Jan; 30(1):251-265. PubMed ID: 32839864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea.
    Carlozzi NE; Downing NR; Schilling SG; Lai JS; Goodnight SM; Miner JA; A Frank S
    Qual Life Res; 2016 Oct; 25(10):2429-2439. PubMed ID: 27141833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT).
    Lunven M; Hamet Bagnou J; Youssov K; Gabadinho A; Fliss R; Montillot J; Audureau E; Bapst B; Morgado G; Reilmann R; Schubert R; Busse M; Craufurd D; Massart R; Rosser A; Bachoud-Lévi AC
    PLoS One; 2021; 16(8):e0253064. PubMed ID: 34424902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties.
    Carlozzi NE; Schilling SG; Lai JS; Perlmutter JS; Nance MA; Waljee JF; Miner JA; Barton SK; Goodnight SM; Dayalu P
    Qual Life Res; 2016 Oct; 25(10):2417-2427. PubMed ID: 27038054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.
    Schobel SA; Palermo G; Auinger P; Long JD; Ma S; Khwaja OS; Trundell D; Cudkowicz M; Hersch S; Sampaio C; Dorsey ER; Leavitt BR; Kieburtz KD; Sevigny JJ; Langbehn DR; Tabrizi SJ;
    Neurology; 2017 Dec; 89(24):2495-2502. PubMed ID: 29142089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
    Hart EP; Dumas EM; Schoonderbeek A; Wolthuis SC; van Zwet EW; Roos RA
    Mov Disord; 2014 Mar; 29(3):320-6. PubMed ID: 24500841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.
    Carlozzi NE; Boileau NR; Paulsen JS; Perlmutter JS; Lai JS; Hahn EA; McCormack MK; Nance MA; Cella D; Barton SK; Downing NR
    J Neurol; 2019 Oct; 266(10):2406-2422. PubMed ID: 31190171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning.
    Carlozzi NE; Hahn EA; Frank SA; Perlmutter JS; Downing ND; McCormack MK; Barton S; Nance MA; Schilling SG;
    J Neurol; 2018 Jan; 265(1):98-107. PubMed ID: 29143208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.